MétaCan
Menu
← Back to cohort
Record W2793286594 · doi:10.1093/jcag/gwy009.156

A156 CONTRASTING THE USE OF 5-ASA IN PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: A CROSS-SECTIONAL ANALYSIS AT A TERTIARY CARE IBD CLINIC

2018· article· en· W2793286594 on OpenAlexaffabout
M Alkhattabi, Vipul Jairath, Nilesh Chande, P Walton-Mennill, James C. Gregor

Bibliographic record

VenueJournal of the Canadian Association of Gastroenterology · 2018
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsWestern University
Fundersnot available
KeywordsMedicineVedolizumabUlcerative colitisAzathioprineInternal medicineCrohn's diseaseUstekinumabInflammatory bowel diseaseInfliximabRandomized controlled trialGastroenterologyMethotrexateDisease

Abstract

fetched live from OpenAlex

M. Alkhattabi, V. Jairath, N. Chande, P. Walton-Mennill, J.C. Gregor Western University, London, ON, Canada 5-ASA is a mainstay of initial induction and maintenance therapy in patients with ulcerative colitis (UC). Although often used in patients with Crohn’s disease (CD), its clinical efficacy in this condition is uncertain. An upcoming Canadian multi centre randomized controlled trial will assess the non-inferiority of 5-ASA withdrawal versus continuation in CD (STATIC Trial NCT03261206) To determine the prevalence of 5-ASA use in patients with CD and contrast it with its use in UC in a tertiary care setting. All patients seen at a single site IBD clinic at London Health Sciences Centre, Victoria Hospital, between January and June 2016 were reviewed. Patients were only included if they had a definite diagnosis of UC or CD. Patients with indeterminate colitis were excluded. If patients were seen on multiple occasions during the study period, characterization of their medication profile was derived from their last visit. Chi squared analysis was used for comparison of proportions. 575 patients were included in the analysis. Of these, 389 (67.7%) had a diagnosis of CD and 186 (32.3%) had a diagnosis of UC. 274/575 (47.6%) patients were on biologics (36.3% on anti-TNF, 7.1% on vedolizumab, 4.2% on ustekinumab). 189/575 (32.9%) patients were on immunomodulators (12.9% on methotrexate, 20% on azathioprine). 50/575 (8.7%) patients were on corticosteroids at their last visit. 5/575 (0.9%) patients were on investigational agents. 175/575 (30.4%) patients were on 5-ASA. When broken down according to diagnosis, 134/186 (72.0%) of patients with UC were taking oral and/or rectal 5-ASA while 41/389 (10.5%) of CD patients were taking this class of medication (p <0.001). When used as monotherapy, 77/134 (57.5%) of UC patients were using 5-ASA as monotherapy while 23/41 (56.1%) of CD patients were using 5-ASA as their only treatment (p = 0.877). 5-ASA is much more commonly used in UC than CD. However, when used as monotherapy the proportion of patients on 5-ASA alone does not appear to vary between the two conditions. The upcoming STATIC trial will add new evidence to determine whether this ongoing use of 5-ASA in CD is efficacious. None

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.005
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.012

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.005
Meta-epidemiology (narrow)0.0000.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.002
Science and technology studies0.0010.000
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.007
GPT teacher head0.228
Teacher spread0.221 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2018
Admission routes2
Has abstractyes

Explore more

Same venueJournal of the Canadian Association of Gastroenterology→Same topicInflammatory Bowel Disease→French-language works237,207→